Edison Issues Flash Update on Atossa Genetics (ATOS)

Sep 02, 2016, 13:54 ET from Edison Investment Research

LONDON, September 2, 2016 /PRNewswire/ --

Atossa Genetics plans to raise up to $2.9m in an equity offering of 1.15m shares, priced at $2.50 per share (a 29% discount to the 30 August 2016 market close of $3.45). The proceeds should help fund Atossa's two active breast cancer therapeutic development programs, intraductal microcatheter (IDMC) administered fulvestrant and oral endoxifen.

     (Logo: http://photos.prnewswire.com/prnh/20130417/608168 )

Based in Seattle, WA, Atossa Genetics is focused on the development of locally administered pharmaceuticals for the treatment of pre-cancer and early-stage breast cancer. Intraductal-microcatheter delivered fulvestrant is currently under investigation in a Phase II study.

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website http://www.edisoninvestmentresearch.com.

About Edison: Edison is an international equity research firm with a team of over 110 analysts, investment and roadshow professionals and works with both large and smaller capitalised companies, blue chip institutional investors, wealth managers, private equity and corporate finance houses to support their capital markets activity. Edison provides services to more than 420 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact: 

Pooya Hemami
Edison Investment Research

Maxim Jacobs
Edison Investment Research


Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:  

LinkedIn http://www.linkedin.com/company/edison-investment-research
YouTube  http://www.youtube.com/edisonitv
Google+  https://plus.google.com/105425025202328783163/posts

SOURCE Edison Investment Research